Therapeutic Drug Monitoring  

empowered by PharmacometrX

News on TDMx

Zurück zur Übersicht


TDMx in Antimicrobial Agents and Chemotherapy

TDMx was used in a study by Barras et al. in cystic fibrosis patients receiving tobramycin.

The authors compared different methods of determining tobramycin exposure in 12 cystic fibrosis patients. They concluded that the tobramycin exposure estimated from the Bayesian method implemented in TDMx was equivalent to true tobramycin exposure determined by the trapezoidal method from eight serum samples per dosing. TDMx, however, required only a single serum sample for this precise estimate of the AUC, which underlines the benefit of using pharmacometric techniques to support the TDM process in a pragmatic way to personalise therapies with highest precision.

Zurück zur Übersicht